Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, … Read more
Affimed NV (AFMD) - Total Assets
Latest total assets as of September 2024: $39.96 Million USD
Based on the latest financial reports, Affimed NV (AFMD) holds total assets worth $39.96 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Affimed NV - Total Assets Trend (2012–2023)
This chart illustrates how Affimed NV’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Affimed NV - Asset Composition Analysis
Current Asset Composition (December 2023)
Affimed NV's total assets of $39.96 Million consist of 86.7% current assets and 13.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.7% |
| Accounts Receivable | $5.33 Million | 5.5% |
| Inventory | $463.00K | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Affimed NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Affimed NV's current assets represent 86.7% of total assets in 2023, an increase from 79.1% in 2012.
- Cash Position: Cash and equivalents constituted 39.7% of total assets in 2023, down from 68.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 5.5% of total assets.
Affimed NV Competitors by Total Assets
Key competitors of Affimed NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Affimed NV - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Affimed NV generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Affimed NV is currently not profitable relative to its asset base.
Affimed NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 3.70 | 3.01 |
| Quick Ratio | 1.93 | 3.67 | 3.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.61 Million | $ 77.94 Million | $ 70.73 Million |
Affimed NV - Advanced Valuation Insights
This section examines the relationship between Affimed NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.06 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -51.5% |
| Total Assets | $97.16 Million |
| Market Capitalization | $2.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Affimed NV's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Affimed NV's assets decreased by 51.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Affimed NV (2012–2023)
The table below shows the annual total assets of Affimed NV from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $97.16 Million | -51.55% |
| 2022-12-31 | $200.51 Million | -10.94% |
| 2021-12-31 | $225.13 Million | +28.12% |
| 2020-12-31 | $175.72 Million | +56.40% |
| 2019-12-31 | $112.36 Million | -3.28% |
| 2018-12-31 | $116.17 Million | +169.18% |
| 2017-12-31 | $43.16 Million | -11.45% |
| 2016-12-31 | $48.74 Million | -38.56% |
| 2015-12-31 | $79.32 Million | +89.27% |
| 2014-12-31 | $41.91 Million | +544.75% |
| 2013-12-31 | $6.50 Million | -9.61% |
| 2012-12-31 | $7.19 Million | -- |